These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37960919)

  • 1. Early progression of chronic histologic lesions in kidney transplant biopsies is not associated with HLA histocompatibility.
    Jabbour R; Heinzel A; Reindl-Schwaighofer R; Gregorich MG; Regele H; Kozakowski N; Kläger J; Fischer G; Kainz A; Becker JU; Wiebe C; Oberbauer R
    Nephrol Dial Transplant; 2024 Apr; 39(5):808-817. PubMed ID: 37960919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies.
    García-Carro C; Dörje C; Åsberg A; Midtvedt K; Scott H; Reinholt FP; Holdaas H; Seron D; Reisæter AV
    Transplantation; 2017 Jun; 101(6):1410-1415. PubMed ID: 27163535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation.
    Meneghini M; Crespo E; Niemann M; Torija A; Lloberas N; Pernin V; Fontova P; Melilli E; Favà A; Montero N; Manonelles A; Cruzado JM; Palou E; Martorell J; Grinyó JM; Bestard O
    Front Immunol; 2020; 11():623276. PubMed ID: 33776988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.
    Senev A; Van Loon E; Lerut E; Coemans M; Callemeyn J; Daniëls L; Kerkhofs J; Koshy P; Kuypers D; Lamarthée B; Sprangers B; Tinel C; Van Craenenbroeck AH; Van Sandt V; Emonds MP; Naesens M
    Am J Kidney Dis; 2022 Dec; 80(6):718-729.e1. PubMed ID: 35690154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of HLA B- and T-cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation.
    Gramkow AM; Baatrup JH; Gramkow ET; Thiesson HC; Koefoed-Nielsen P
    Pediatr Transplant; 2024 Aug; 28(5):e14773. PubMed ID: 38808702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
    Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
    Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplet mismatch analysis and allograft outcome across racially diverse groups in a pediatric transplant cohort: a single-center analysis.
    Philogene MC; Amin A; Zhou S; Charnaya O; Vega R; Desai N; Neu AM; Pruette CS
    Pediatr Nephrol; 2020 Jan; 35(1):83-94. PubMed ID: 31599339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study.
    Meszaros M; Niemann M; Ursic-Bedoya J; Faure S; Meunier L; Rivière B; Costes-Martineau V; Thevenin C; Pageaux GP
    Transpl Immunol; 2020 Apr; 59():101272. PubMed ID: 32061667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of HLA molecular level mismatching in ethnically diverse kidney transplant recipients receiving a steroid-sparing immunosuppression protocol.
    Santos E; Spensley K; Gunby N; Worthington J; Roufosse C; Anand A; Willicombe M
    Am J Transplant; 2024 Jul; 24(7):1218-1232. PubMed ID: 38403189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of T and B Cell Epitopes to Predict the Risk of
    Sakamoto S; Iwasaki K; Tomosugi T; Niemann M; Spierings E; Miwa Y; Horimi K; Takeda A; Goto N; Narumi S; Watarai Y; Kobayashi T
    Front Immunol; 2020; 11():2000. PubMed ID: 32973806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort.
    Reindl-Schwaighofer R; Heinzel A; Kainz A; van Setten J; Jelencsics K; Hu K; Loza BL; Kammer M; Heinze G; Hruba P; Koňaříková A; Viklicky O; Boehmig GA; Eskandary F; Fischer G; Claas F; Tan JC; Albert TJ; Patel J; Keating B; Oberbauer R;
    Lancet; 2019 Mar; 393(10174):910-917. PubMed ID: 30773281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?
    Wen J; Basu A; Bentall A; Henderson N; Dukek B; Gandhi M; Schinstock C
    Hum Immunol; 2021 Apr; 82(4):240-246. PubMed ID: 33618904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
    Yanyiam P; Kantachuvesiri S; Thammanichanond D
    Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of human leukocyte antigen immunologic risk stratification methods in lung transplantation.
    Hiho SJ; Levvey BJ; Diviney MB; Snell GI; Sullivan LC; Westall GP
    Am J Transplant; 2024 May; 24(5):827-838. PubMed ID: 37981213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study.
    Castro A; Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    HLA; 2017 Nov; 90(5):267-275. PubMed ID: 28776960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIRCHE-II scores prove useful as a predictive biomarker among kidney transplant recipients with rejection: An analysis of indication and follow-up biopsies.
    Spitznagel T; Matter LS; Kaufmann YL; Nilsson J; von Moos S; Schachtner T
    Front Immunol; 2022; 13():949933. PubMed ID: 36059499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.